Exscientia

aid: exscientia
name: Exscientia
description: 'Exscientia was an Oxford UK-based AI-driven precision medicine and drug design company, founded in 2012 as a
  spin-out from the University of Dundee. Its platform combined generative chemistry (Centaur Chemist) with patient tissue-based
  screening (EVE, an automated single-cell platform for testing drug candidates directly against patient-derived tumor samples)
  to design small-molecule drug candidates faster and at lower cost than conventional pharma R&D. Notable firsts included
  EXS-21546 (an A2A antagonist developed with Evotec), DSP-1181 (the first AI-designed molecule to enter human clinical trials,
  with Sumitomo Dainippon Pharma), and DSP-0038 (a dual 5-HT1A/5-HT2A modulator for Alzheimer''s psychosis). Exscientia maintained
  active pharma partnerships with Sanofi, Bristol Myers Squibb, Bayer, Sumitomo, and Merck KGaA. Exscientia was acquired by
  Recursion Pharmaceuticals (NASDAQ: RXRX) in an all-stock deal that closed in November 2024; the combined company operates
  under the Recursion brand and the legacy exscientia.ai website now redirects to recursion.com. The Exscientia name persists
  primarily through its GitHub organization, which continues to host open-source scientific Python packages for molecular
  predictive modelling (molflux), physics-based ML potentials (physicsml), antibody structure prediction (abodybuilder3),
  and biomolecular simulation (biosimspace) used by the wider computational chemistry and structural biology community. Exscientia
  did not expose any public commercial APIs, SDKs, or developer products before or after the merger; platform access was always
  delivered through collaborative drug-discovery agreements.'
type: Index
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
position: Provider
access: 3rd-Party
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/exscientia.png
tags:
- Drug Discovery
- Drug Design
- AI Drug Design
- Precision Medicine
- Biotech
- Pharmaceuticals
- Generative Chemistry
- Centaur Chemist
- EVE Platform
- Patient-Derived Screening
- Oncology
- Small Molecules
- Computational Chemistry
- Machine Learning
- Open Source
- Acquired
url: https://raw.githubusercontent.com/api-evangelist/exscientia/refs/heads/main/apis.yml
created: '2026-05-24'
modified: '2026-05-24'
specificationVersion: '0.20'
apis: []
common:
- type: DomainSecurity
  url: security/exscientia-domain-security.yml
- type: Website
  url: https://www.recursion.com
- type: LegacyWebsite
  url: https://www.exscientia.ai
- type: AcquisitionAnnouncement
  url: https://ir.recursion.com/news-releases/news-release-details/recursion-and-exscientia-combine-create-leading-techbio-company
- type: AcquisitionClosing
  url: https://ir.recursion.com/news-releases/news-release-details/recursion-completes-business-combination-exscientia
- type: ParentCompany
  url: https://www.recursion.com
- type: GitHubOrganization
  url: https://github.com/Exscientia
- type: Molflux
  url: https://github.com/Exscientia/molflux
- type: PhysicsML
  url: https://github.com/Exscientia/physicsml
- type: ABodyBuilder3
  url: https://github.com/Exscientia/abodybuilder3
- type: BioSimSpace
  url: https://github.com/Exscientia/biosimspace
- type: StableNetGuardOwl
  url: https://github.com/Exscientia/StableNetGuardOwl
- type: RDVC
  url: https://github.com/Exscientia/rdvc
- type: Wikipedia
  url: https://en.wikipedia.org/wiki/Exscientia
- type: Crunchbase
  url: https://www.crunchbase.com/organization/exscientia
- type: LinkedIn
  url: https://www.linkedin.com/company/exscientialtd
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com